Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain Estela Moreno-Martínez; Javier de la Serna-Torraba; Vicente Escudero-Vilaplana; José Ángel Hernández-Rivas; Marina Sánchez-Cuervo; Raquel Sánchez-Hernández;

Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes Garcia-Diaz; María Larrosa-Garcia; Gomez-Alonso; Mara Cruellas; Enriqueta Felip; Teresa Macarulla; Anna Farriols; Maria J. Carreras;